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OBJECTIVES: To characterize patients suffering from restless
legs syndrome (RLS) and assess their annual health care
resources consumption in comparison with a population of
average ambulatory patients seen by General Practitioners (GPs),
in France. METHODS: This study was based on anonymous
individual longitudinal medical records of adult patients suffer-
ing from RLS provided by physicians from a permanent panel of
representative French GPs. RLS was deﬁned accordingly to
established diagnostic criteria. Patients with at least one com-
plaint of legs and/or sleep symptoms suggestive of RLS in 2003
were included. Data about patients’ socio-demographic charac-
teristics, clinical status, medical resources consumption and sick
leaves over one year were collected retrospectively. For the cost
comparison, RLS patients were matched for sex and age to a cor-
responding random population of patients followed by the same
GPs. Average annual costs in € were estimated from the per-
spective of Health Insurance. RESULTS: A total of 515 RLS
patients were included. Mean age was 63.8 years and 76% were
female. 14% of patients had both complaints of leg and sleep
symptoms, 59% only leg troubles and 27% only sleep distur-
bances. All together, RLS patients consumed signiﬁcantly (p <
0.0001) more health care resources than those from the com-
parison group. On average in 2003, they saw 11.6 times their
GPs (versus 4.6 in the comparison group), 7 investigations were
prescribed (versus 4.3) and they had had 46.8 drug prescriptions
(versus 16.5). The mean annual medical cost of RLS patients’
follow-up by GPs was twice higher than that of average con-
sulting patients (840€ versus 391€, p < 0.0001). CONCLU-
SIONS: This study shows that patients satisfying to validated
diagnostic criteria consumed signiﬁcantly more medical
resources than “ordinary” patients in primary care bearing in
mind that RLS remains an unknown and under-diagnosed con-
dition. This population deserves thus a special attention in order
to optimize the treatment.
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OBJECTIVES: Idiopathic RLS (Ekbom syndrome) is a sensori-
motor disorder that leads to disrupted sleep and poor quality of
life. Until now, there have been no internationally approved
treatments for this disorder. This study evaluated costs and out-
comes resulting from the use of ropinirole in patients with RLS.
METHODS: Data were combined from 553 patients enrolled in
two matching, pivotal, randomized, 12-week, double-blind,
placebo-controlled studies. Patients with moderate-to-severe
RLS received ropinirole or placebo, with a maximum allowable
dose of 4mg/day. The primary outcome measure was the Inter-
national Restless Legs Scale (IRLS). IRLS scores at baseline and
study endpoint were mapped to the multi-attribute utility instru-
ment EQ-5D based on expert opinion to derive Quality-Adjusted
Life Years (QALYs). Costs of study drug, concomitant neuro-
logical medications and cost of adverse events were applied in
the model from the perspective of the UK NHS. Lower cost per
QALY gained indicates better cost-effectiveness. RESULTS:
Based on combined analysis of the entire treatment population
over 12 weeks, the QALYs gained for ropinirole and placebo
were 0.095 (0.082–0.106) and 0.075 (0.063–0.086), respec-
tively. The mean costs per patient for ropinirole and placebo
were £210.52 (£197–£223) and £42.34 (£34–£53), respectively.
The incremental QALYs and costs were 0.020 (0.002–0.037) and
£168.18 (£150–£187), respectively, resulting in an incremental
cost per QALY of £8405 (£4557–£41,524). Extrapolation of
IRLS scores at trial endpoint to 52 weeks improved the incre-
mental QALY to £6748. For patients reporting more severe sleep
disturbance or more severe symptoms at baseline, the cost-effec-
tiveness ratios improved to £5810 (£3210–£20,177) and £4587
(£2881–£10,508), respectively. CONCLUSIONS: In the absence
of an active-treatment comparator, this analysis found that treat-
ment of moderate-to-severe RLS with ropinirole is cost-effective
compared with placebo using conventional UK cost-effectiveness
standards, particularly in patients with more severe sleep distur-
bance and severe RLS symptoms at baseline.
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OBJECTIVE: Assess utilization of Dysport and BOTOX for cer-
vical dystonia and blepharospasm and compute the cost conse-
quences of toxin selection. METHODS: Six European study sites
abstracted drug utilization data from the records of their patients
who had received Dysport then BOTOX or BOTOX then
Dysport in a drug crossover that occurred in clinical practice. To
reduce potential selection bias and confounding variables,
patient records were screened for study inclusion/exclusion cri-
teria during scheduled clinic visits. Patients were screen-qualiﬁed
if they were 18 years of age, medically stable, responsive to per-
sistent toxin therapy for 1 year before and after drug crossover,
did not receive other medications that affect neuromuscular
transmission, and were not involved in another drug study.
RESULTS: A total of 132 screen-qualiﬁed patients were assessed.
Ratios of mean dose (units) Dysport: BOTOX ranged from 2 :1
to 11 :1, with 88% of patients greater than or equal to 3 :1,
regardless of study site or direction of drug crossover. When
current UK pricing for BOTOX and Dysport is applied to dis-
tribution of ratios, patients started on Dysport and switched to
BOTOX (N = 94) result in an incremental net savings of £1572.4
or an average savings of £16.7 per patient. When patients were
started on BOTOX and switched to Dysport (N = 38), an incre-
mental net cost of £252.9 or an average cost of £6.7 per patient
is realized. CONCLUSION: BOTOX utilization likely leads to
net cost savings compared with Dysport based on utilization and
current pricing for the UK.
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OBJECTIVES: To compare the costs of PD when using rasagi-
line and entacapone to treat patients that experienced motor ﬂuc-
tuations. METHODS: An 18-week randomised double-blind
controlled clinical trial (RCT) LARGO, evaluating the safety and
efﬁcacy of rasagiline 1mg/d, entacapone 200mg with levodopa
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dosing or placebo, was conducted in levodopa-treated patients
with motor ﬂuctuations. Patients were then followed in a double-
blind extension study (patients treated by active drug remain on
their initial treatment). In some countries, patients were asked to
participate in a pharmacoeconomic sub-study (PE). A cost analy-
sis (in euros year 2003) examined resource utilisation, costs and
caregiver burden of patients taking rasagiline versus entacapone.
RESULTS: A total of 62 patients participated in each active treat-
ment arm. Reduction in OFF Time after 18 weeks was compa-
rable in each arm. Reduction in UPDRS total score after six
additional months was similar in each arm. Both treatments were
associated with comparable resource uses at each PE visit. Health
care costs (except drugs) were 105€ for rasagiline and 88€ for
entacapone. Total costs (health care + sick leave) were 107€ for
rasagiline and 156€ for entacapone. Caregiver’s Relative Stress
Scale scores after four months of treatment were 34.5 for rasag-
iline and 33.9 for entacapone and 37.5 and 33.9, respectively,
after 6 additional months. Difference between treatments in total
caregiver’s time on the entire period (9 months) was 34.9 hours
in favour of entacapone. None of the differences were statisti-
cally signiﬁcant. CONCLUSIONS: Resource use was lower than
in routine population. Treatment with rasagiline and entacapone
results in similar resource use and caregiver’s burden. This is in
line with the comparable efﬁcacy of both treatments on motor
ﬂuctuations and activities of daily living. Thus, costs of treat-
ments will have a clear inﬂuence on the total healthcare costs
difference between both treatments.
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OBJECTIVES: Choosing an appropriate antiepileptic medica-
tion (AED) is a complex decision, especially in a pediatric pop-
ulation where there is greater multiplicity of epileptic conditions,
and greater heterogeneity with respect to syndrome types, causes
and prognoses compared with adults. With a dearth of well-
designed, long-term trials, economic modelling techniques must
be employed to evaluate the cost-effectiveness of treatment
options. An economic model of the treatment of refractory
partial seizures was developed to provide the ﬁrst assessment of
the cost-effectiveness of topiramate as adjunctive treatment in
children. METHODS: A Markov model was developed to
combine data from clinical trials, cost-of illness studies, epilepsy-
related mortality surveys, and utility studies to model long-term
treatment. Due to lack of data, in some cases information relat-
ing to adults had to be adjusted and used. Only lamotrigine was
evaluated in a pediatric population in a trial similar in design to
the one available for topiramate. Based on these trials, the model
was used to evaluate the cost-effectiveness of adjunctive treat-
ment with 6mg/kg/day topiramate against 8mg/kg/day lamot-
rigine. The expected costs associated with each treatment were
calculated for 2002 from the perspective of the UK NHS.
Changes in quality of life were measured by the EQ-5D. A prob-
abilistic sensitivity analysis was undertaken. RESULTS: There is
little difference in response rates between adjunctive lamotrigine
and adjunctive topiramate treatments for children. However, in
the clinical trials driving the model topiramate was associated
with a 5% seizure freedom rate while no one became seizure free
in the lamotrigine trial. As a consequence, topiramate was asso-
ciated with slightly higher QALY gains compared to lamotrig-
ine. Topiramate treatment was also cheaper and therefore had a
higher probability of being cost-effective. CONCLUSIONS:
Further research is warranted in childhood epilepsy in almost all
areas. This exploratory analysis shows topiramate to be a cost-
effective treatment option.
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OBJECTIVES: Stroke is the largest cause of severe disability in
adults. Approximately 40% of survivors at 12-months will have
upper or lower limb spasticity. Upper limb spasticity is particu-
larly debilitating as patients may experience difﬁculties in routine
daily activities. Basic treatment includes physiotherapy and oral
antispastic agents. The objective of the present study was to
analyse the costs and outcomes of BTX-A injections as add-on
to the basic treatment for ﬂexed wrist/clenched ﬁst spasticity
compared to basic treatment. METHODS: Due to absence of
empirical data, a Delphi expert panel of Swedish and Finnish
neurologists was convened to estimate treatment outcomes and
resource utilisation. On average the experts treated 125 patients
per year with BTX-A. Unit costs were obtained from ofﬁcial
Swedish and Finnish sources. A decision analytic model was used
to compare treatments. The model included outcomes, post-
stroke mortality and treatment costs. The model used a health
care sector perspective and a 12-month horizon. RESULTS: The
Finnish experts estimated that 70% reached their treatment goal
with BTX-A compared with 34% with basic treatment (66% /
32% when adjusted for mortality). Medication costs were higher
with BTX-A (1791€ vs. 205€). However, rehabilitation costs
(neurologist, GP, nurse, physiotherapy) were lower due to
improved treatment outcome (13,097€ vs. 15,940€). Hospitali-
sation costs were equal (3055€). Total costs with BTX-A were
slightly lower. The weekly need for physiotherapy was the major
cost driver. Several sensitivity analyses showed robust results.
Results from Sweden will be reported in the ﬁnal presentation.
CONCLUSIONS: The analysis showed that a greater proportion
of patients whose treatment included BTX-A therapy reached
their treatment goals and as a consequence this reduced the total
physiotherapy resources required over time. Moreover the analy-
sis showed that BTX-A therapy was slightly cheaper. Conse-
quently neurologists should consider BTX-A as a treatment for
post-stroke spastic patients.
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OBJECTIVE: Describe health care resources used by Spanish
primary care physicians (PCP) in patients who attend for ﬁrst
time due to subjective memory complaints or cognitive impair-
ment. METHODS: Observational, longitudinal, multicentric
and naturalistic study in which 105 PCP of all-over Spain par-
ticipated. Patients 60 years or older attending to PCP due to over-
6-month subjective memory complaints or cognitive impairment.
